SCHEMBL1709534

SCHEMBL1709534

O=C(Nc1ccc(F)cn1)C(Oc1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.65
GCK P35557 1/20 0.57
CYP3A4 P08684 4/20 0.47
GRM5 P41594 3/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
BRD4 O60885 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43
MAPT P10636 1/20 0.43
MEN1 O00255 1/20 0.43
CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL933927 0.99 FFAR2 (0.63) FFAR2GCKCYP3A4GRM5RAB9A
SCHEMBL1709590 0.94 FFAR2 (0.58) FFAR2GCKCYP3A4GRM5RAB9A
Hydrochloric Acid SCHEMBL934919 0.93 FFAR2 (0.57) FFAR2GCKCYP3A4GRM5RAB9A
SCHEMBL1709567 0.90 GCK (0.61) FFAR2GCKRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL933546 0.88 GCK (0.60) FFAR2GCKRAB9ANPC1SMN1; SMN2
SCHEMBL1709544 0.85 GCK (0.57) FFAR2GCKRAB9ANPC1TSHR
SCHEMBL1709591 0.84 GCK (0.56) FFAR2GCKRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL933840 0.84 GCK (0.56) FFAR2GCKRAB9ANPC1SMN1; SMN2
SCHEMBL1709595 0.84 GCK (0.56) FFAR2GCKCYP3A4RAB9ANPC1
SCHEMBL1709603 0.84 GCK (0.56) FFAR2GCKRAB9ANPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 FFAR2 117/4885GCK 2816/4885CYP3A4 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.